The FTC and Illumina’s Grail: The Tipline for 23 August 2021

Antitrust is not usually a matter of life and death, but administrative law judge D Michael Chappell is going to hear otherwise this week. Starting today, Federal Trade Commission staff will square off with Illumina over the DNA-sequencing company’s completed acquisition of Grail, which is developing an innovative cancer-screening test. Both the government and the merging parties are expected to argue that their opponent is trying to obstruct this life-saving technology.

Get unlimited access to all Global Competition Review content